Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 08:50:00 13/09/2024 pm IST 5-day change 1st Jan Change
918.50 DKK +0.47% Intraday chart for Novo Nordisk A/S +3.76% +31.57%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
Eli Lilly invests $1.8 billion in Ireland sites to scale up Alzheimer's, obesity drug production RE
NOVO NORDISK : Deutsche Bank keeps its Buy rating ZD
Roche shares drop on side effects result in early-stage obesity pill trial RE
Health Care Down on Cyclical Bias -- Health Care Roundup DJ
Sector Update: Health Care Stocks Narrowly Mixed Premarket Wednesday MT
Novo Nordisk's Experimental Obesity Pill Could Be More Effective With Extended Use DJ
NOVO NORDISK : JP Morgan reiterates its Buy rating ZD
NOVO NORDISK : Gets a Neutral rating from UBS ZD
Novo Nordisk Reports Positive Results of Phase 3a Trial of Anti-Obesity Drug Liraglutide in Children MT
Health Care Up on Defensive Bias -- Health Care Roundup DJ
Weight-loss market to see 16 new drugs by 2029, report estimates RE
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Index Set to End Week 3.7% Lower MT
Novo Nordisk to present advances in diabetes treatment CF
Are thematic ETFs useless? Our Logo
Veeva Systems: leader in cloud solutions for the life sciences industry Our Logo
NOVO NORDISK : Gets a Neutral rating from Berenberg ZD
Health Care Declines as Risk Aversion Weighs - Health Care Roundup DJ
European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading MT
NOVO NORDISK : JP Morgan remains its Buy rating ZD
How to find and check an Ozempic batch number RE
Ozempic shortages will hit some EU countries only - Novo Nordisk RE
Ozempic shortages in EU will not affect all member states - Novo Nordisk RE
US will still pay at least twice as much after negotiating drug prices RE
Novo Nordisk's Ozempic shortage expected to continue into Q4 RE
Biden Commends Eli Lilly for Cheaper Zepbound Version, Vows to Negotiate Lower Obesity Drug Prices MT
Chart Novo Nordisk A/S
More charts
Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Employees
69,260
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
914.20DKK
Average target price
967.54DKK
Spread / Average Target
+5.83%
Consensus
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. News Novo Nordisk A/S
  5. Novo Nordisk: Q2 miss; recent market fears should be capitalised on by long-term investors
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities. Last hours!
BENEFIT NOW